Keytruda, Opdivo’s Retention Of Hepatocellular Carcinoma Indication May Depend On Ongoing Studies

US FDA advisory committee to consider whether new studies can take place of failed confirmatory trials to support accelerated approvals. The agency also wants the panel to consider the changing landscape of HCC following the approval of atezolizumab in combination with bevacizumab.